DAX22.456 -1,0%ESt505.329 -1,0%Top 10 Crypto11,54 -5,3%Dow41.579 -1,7%Nas17.327 -2,7%Bitcoin77.333 -4,2%Euro1,0821 +0,2%Öl73,58 -0,6%Gold3.084 +0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Tesla A1CX3T NVIDIA 918422 RENK RENK73 HENSOLDT HAG000 Novo Nordisk A3EU6F Mercedes-Benz Group (ex Daimler) 710000 Volkswagen (VW) vz. 766403 Lufthansa 823212 thyssenkrupp 750000 Porsche PAG911 BYD A0M4W9 Commerzbank CBK100 DEUTZ 630500 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Zölle belasten weiter: DAX geht schwächer ins Wochenende -- CureVac mit Erfolg im Patentstreit mit BioNTech -- CoreWeave-IPO, NEL, RENK, Novo Nordisk, Deutsche Bank, IONOS im Fokus
Top News
DAX in KW 13: Diese Aktien gehörten zu den Gewinnern und Verlierern DAX in KW 13: Diese Aktien gehörten zu den Gewinnern und Verlierern
Verluste in New York: S&P 500 liegt am Mittag im Minus Verluste in New York: S&P 500 liegt am Mittag im Minus
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Silber vor dem Höhenflug - profitieren Sie von der Entwicklung und investieren Sie in Silber bei philoro. Zum Silbershop.

Immunic Aktie

NeuKaufenVerkaufen
Immunic Aktien-Sparplan
1,16 EUR +0,05 EUR +4,71 %
FSE
1,19 USD -0,05 USD -3,64 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.100,23 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PHD4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4525EP1011

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIMUX

Immunic Aktien News

DatumMeistgelesen
EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in March
PR NewswireImmunic to Participate in Scientific and Investor Conferences in March
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Wer­bungImmunic-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
PR NewswireImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in February
PR NewswireImmunic to Participate in Investor and Scientific Conferences in February
EQS GroupEQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
PR NewswireImmunic Highlights 2024 Accomplishments and Upcoming Milestones
EQS GroupEQS-News: Immunic, Inc. to Participate in Investor Conference in December
PR NewswireImmunic, Inc. to Participate in Investor Conference in December
EQS GroupEQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
PR NewswireImmunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
EQS GroupEQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
EQS GroupEQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November
PR NewswireImmunic to Participate in Industry, Scientific and Investor Conferences in November
EQS GroupEQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
PR NewswireImmunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
PR NewswireImmunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
EQS GroupEQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
PR NewswireImmunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
EQS GroupEQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
EQS GroupEQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
PR NewswireImmunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
PR NewswireImmunic Appoints Jason Tardio as Chief Operating Officer and President
PR NewswireImmunic to Participate in Industry and Scientific Conferences in June
PR NewswireImmunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic to Participate in Investor and Scientific Conferences in May
PR NewswireImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR NewswireImmunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunolog...
Wer­bung

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.